Search Results

Expression of the Fluoropyrimidine-Metabolizing Enzymes in Bladder Cancers as Measured by the Danenberg Tumor Profile

Authors: Naoe, Michio; Ogawa, Yoshio; Morita, Jun; Shichijo, Takeshi; Fuji, Khozo; Takeshita, Kumiko; Kushima, Miki; Terao, Shuji; Yamochi, Toshiko; Ota, Hidekazu

Source: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Volume 18, Number 4, 2009 , pp. 153-162(10)

Publisher: Cognizant Communication Corporation

ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer

Authors: Ryu, Min-Hee; Kang, Yoon-Koo

Source: Expert Review of Anticancer Therapy, Volume 9, Number 12, December 2009 , pp. 1745-1751(7)

Publisher: Expert Reviews

Much fluoropyrimidine toxicity may be avoidable through pretreatment testing for dihydropyrimidine dehydrogenase (DPD) polymorphisms

Source: Reactions, Volume 1, Number 1281, 2009-12-05 , pp. 5-5(1)

Publisher: Adis International

Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer

Authors: Adema, A. D.; Bijnsdorp, I. V.; Sandvold, M. L.; Verheul, H. M.; Peters, G. J.

Source: Current Medicinal Chemistry, Volume 16, Number 35, December 2009 , pp. 4632-4643(12)

Publisher: Bentham Science Publishers

Different histological types of non-small cell lung cancer have distinct folate and DNA methylation levels

Authors: Jin, MingJi; Kawakami, Kazuyuki; Fukui, Yousuke; Tsukioka, Sayaka; Oda, Makoto; Watanabe, Go; Takechi, Teiji; Oka, Toshinori; Minamoto, Toshinari

Source: Cancer Science, Volume 100, Number 12, December 2009 , pp. 2325-2330(6)

Publisher: Blackwell Publishing

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer

Authors: Okines, A. F. C.; Norman, A. R.; McCloud, P.; Kang, Y.-K.; Cunningham, D.

Source: Annals of Oncology, Volume 20, Number 9, 24 September 2009 , pp. 1529-1534(6)

Publisher: Oxford University Press

Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature

Authors: Merl, MY; Hoimes, CJ; Pham, T; Saif, M Wasif

Source: Expert Opinion on Investigational Drugs, Volume 18, Number 9, September 2009 , pp. 1257-1264(8)

Publisher: Informa Healthcare

Advances in the Pharmacological Treatment of Gastro-Oesophageal Cancer

Authors: >Anna Dorothea Wagner,; Wedding, Ulrich

Source: Drugs & Aging, Volume 26, Number 8, 1 August 2009 , pp. 627-646(20)

Publisher: Adis International

Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer

Authors: Kong, Sun-Young; Lim, Hyeong-Seok; Nam, Byung-Ho; Kook, Myeong-Cherl; Kim, Young-Woo; Won Ryu, Keun; Lee, Jun Ho; Choi, Il Ju; Lee, Jin Soo; Park, Young-Iee; Kim, Noe Kyeong; Park, Sook Ryun

Source: Pharmacogenomics, Volume 10, Number 7, July 2009 , pp. 1147-1155(9)

Publisher: Future Medicine

Successful treatment of refractory bronchioloalveolar carcinoma with S-1 (oral fluoropyrimidine)

Authors: KOBAYASHI, Seiichi; FUJINO, Naoya; SUZUKI, Satoshi; YANAI, Masaru

Source: Respirology, Volume 14, Number 5, July 2009 , pp. 771-772(2)

Publisher: Blackwell Publishing

Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment

Authors: Amstutz, Ursula; Farese, Simone; Aebi, Stefan; Largiadèr, Carlo R

Source: Pharmacogenomics, Volume 10, Number 6, June 2009 , pp. 931-944(14)

Publisher: Future Medicine

Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment

Author: Shimoyama, Shouji

Source: Journal of Gastroenterology and Hepatology, Volume 24, Number 6, June 2009 , pp. 970-981(12)

Publisher: Blackwell Publishing

The impact of primary tumour origins in patients with advanced oesophageal, oesophagogastric junction and gastric adenocarcinomaindividual patient data from 1775 patients in four randomised controlled trials

Authors: Chau, I.; Norman, A. R.; Cunningham, D.; Oates, J.; Hawkins, R.; Iveson, T.; Nicolson, M.; Harper, P.; Seymour, M.; Hickish, T.

Source: Annals of Oncology, Volume 20, Number 5, 6 May 2009 , pp. 885-891(7)

Publisher: Oxford University Press

Retrospective Analysis of S-1 Monotherapy in Patients with Metastatic Colorectal Cancer After Failure to Fluoropyrimidine and Irinotecan or to Fluoropyrimidine, Irinotecan and Oxaliplatin

Authors: Yasui, Hirofumi; Yoshino, Takayuki; Boku, Narikazu; Onozawa, Yusuke; Hironaka, Shuichi; Fukutomi, Akira; Yamazaki, Kentaro; Taku, Keisei; Kojima, Takashi; Machida, Nozomu

Source: Japanese Journal of Clinical Oncology, Volume 39, Number 5, 31 May 2009 , pp. 315-320(6)

Publisher: Oxford University Press

A Phase 2 Clinical Trial of Panitumumab Monotherapy in Japanese Patients with Metastatic Colorectal Cancer

Authors: Muro, Kei; Yoshino, Takayuki; Doi, Toshihiko; Shirao, Kuniaki; Takiuchi, Hiroya; Hamamoto, Yasuo; Watanabe, Hiroyuki; Yang, Bing-Bing; Asahi, Daisuke

Source: Japanese Journal of Clinical Oncology, Volume 39, Number 5, 31 May 2009 , pp. 321-326(6)

Publisher: Oxford University Press

Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-α in a hemodialysis patient

Authors: Katamura, Yoshio; Aikata, Hiroshi; Kimura, Yuki; Azakami, Takahiro; Kawaoka, Tomokazu; Takaki, Shintaro; Waki, Koji; Hiramatsu, Akira; Kawakami, Yoshiiku; Takahashi, Shoichi; Chayama, Kazuaki

Source: Hepatology Research, Volume 39, Number 4, April 2009 , pp. 415-420(6)

Publisher: Blackwell Publishing

Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage

Authors: Wilson, Peter M.; Fazzone, William; LaBonte, Melissa J.; Lenz, Heinz-Josef; Ladner, Robert D.

Source: Nucleic Acids Research, Volume 37, Number 1, 27 January 2009 , pp. 78-95(18)

Publisher: Oxford University Press

S-1 and Gemcitabine as an Outpatient-based Regimen in Patients with Advanced or Metastatic Pancreatic Cancer

Authors: Kim, Min Kyoung; Lee, Kyung Hee; Jang, Byung Ik; Kim, Tae Nyeun; Eun, Jong Ryul; Bae, Sung Hwa; Ryoo, Hun Mo; Lee, Sun Ah; Hyun, Myung Soo

Source: Japanese Journal of Clinical Oncology, Volume 39, Number 1, 24 January 2009 , pp. 49-53(5)

Publisher: Oxford University Press

Phase II study of S-1 and irinotecan combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Korean Cancer Study Group Protocol ST05-02

Authors: KANG, Hye J; CHO, Sang H; OH, Suk J; YANG, Sung H; LEE, Moon H; SONG, Eun-Kee; CHUNG, Hyun C; NA, Im I; RYOO, Baek-Yeol

Source: Asia-Pacific Journal of Clinical Oncology, Volume 5, Number 1, March 2009 , pp. 46-54(9)

Publisher: Blackwell Publishing

S-1: a promising new oral fluoropyrimidine derivative

Authors: Saif, Muhammad Wasif; Syrigos, Kostas N; Katirtzoglou, Nikos A

Source: Expert Opinion on Investigational Drugs, Volume 18, Number 3, March 2009 , pp. 335-348(14)

Publisher: Informa Healthcare